Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
| العنوان: | Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study |
|---|---|
| المؤلفون: | Jesús F. San-Miguel, P. Joy Ho, Christopher Chiu, Xiang Qin, Meletios A. Dimopoulos, Nizar J. Bahlis, Philippe Moreau, Naoki Takezako, Kihyun Kim, Jon Ukropec, Sonali Trivedi, Darrell White, Lotfi Benboubker, Gordon Cook, Linda Okonkwo, Ming Qi, Maria Krevvata, Merav Leiba, Jonathan L. Kaufman |
| المصدر: | Leukemia |
| بيانات النشر: | Springer Science and Business Media LLC, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Male, Cancer Research, medicine.medical_specialty, Population, Salvage therapy, Gastroenterology, Dexamethasone, Article, Medical research, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, education, Lenalidomide, Survival rate, Multiple myeloma, Aged, Cancer, Salvage Therapy, education.field_of_study, business.industry, Antibodies, Monoclonal, Daratumumab, Hematology, Prognosis, medicine.disease, Minimal residual disease, Thalidomide, Survival Rate, Oncology, Drug Resistance, Neoplasm, Female, Neoplasm Recurrence, Local, Multiple Myeloma, business, Follow-Up Studies, medicine.drug |
| الوصف: | In POLLUX, daratumumab (D) plus lenalidomide/dexamethasone (Rd) reduced the risk of disease progression or death by 63% and increased the overall response rate (ORR) versus Rd in relapsed/refractory multiple myeloma (RRMM). Updated efficacy and safety after >3 years of follow-up are presented. Patients (N = 569) with ≥1 prior line received Rd (lenalidomide, 25 mg, on Days 1–21 of each 28-day cycle; dexamethasone, 40 mg, weekly) ± daratumumab at the approved dosing schedule. Minimal residual disease (MRD) was assessed by next-generation sequencing. After 44.3 months median follow-up, D-Rd prolonged progression-free survival (PFS) in the intent-to-treat population (median 44.5 vs 17.5 months; HR, 0.44; 95% CI, 0.35–0.55; P P P –5; 30.4 vs 5.3%; P P P |
| تدمد: | 1476-5551 0887-6924 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fed58b2818b96cb322be94413a2dc7f7Test https://doi.org/10.1038/s41375-020-0711-6Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....fed58b2818b96cb322be94413a2dc7f7 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14765551 08876924 |
|---|